The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase-Ib study of TRK-950 combined with anticancer treatment regimens in patients with gastric and gastro-esophageal junction (GEJ) cancer.
 
Philippe Alexandre Cassier
Honoraria - Amgen
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Janssen Oncology; OSE Immunotherapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - OSE Immunotherapeutics; Roche
 
Marc Ryan Matrana
No Relationships to Disclose
 
Diana L. Hanna
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim
 
Ben George
Consulting or Advisory Role - Bayer; Boston Scientific; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Ipsen; Roche/Genentech; Taiho Pharmaceutical; TERUMO
Research Funding - Boehringer Ingelheim (Inst); GlycoNex (Inst); Helix BioPharma (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Roche (Inst); Roche/Genentech (Inst); Sirnaomics (Inst); Taiho Pharmaceutical (Inst); Tolero Pharmaceuticals (Inst); Toray Industries (Inst); Trishula Therapeutics (Inst)
 
Sunil Sharma
Stock and Other Ownership Interests - Barricade Therapeutics; Beta Cat Pharmaceuticals; ConverGene; Elevar Therapeutics; HLB; Salarius Pharmaceuticals; Stingray Therapeutics
Honoraria - Array BioPharma
Consulting or Advisory Role - Barricade Therapeutics; Barricade Therapeutics; Barricade Therapeutics; Celularity; Dracen; Elevar Therapeutics; Elevar Therapeutics; Elevar Therapeutics
Research Funding - AADi; Amal Therapeutics; Celgene; Dracen; Honor Health; Honor Health; Inhibrx; Merck; Nektar; Novartis; Plexxikon; Sirnaomics; Syndax; Takeda; Tesaro; Toray Industries; Zai Lab
Patents, Royalties, Other Intellectual Property - Compositions and Methods for the Treatment of Cancer. Provisional Application Serial No. 63/270,005.; Compositions and Methods for the Treatment of Coronavirus Infection. Provisional Application Serial No.: 63/005,780. Filing Date: 4/6/2020. TGen Ref No: 200401- 299PROV.; Imidazolopyrazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,954. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV2. Seed Ref. No.: 910255.403P1.; Imidazolopyridazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,951. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV1. Seed Ref. No.: 910255.402P1.; Imidazolotriazine Compounds and Methods of Use Thereof. Provisional Application No.: 63/079,955. Filing Date: 9/17/2020. TGen Ref No.: 200727-304PROV3. Seed Ref. No.: 910255.404P1.; Imidazopyridazine and Imidazopyrazine Compounds and Methods of Use Thereof. International PCT Patent Application No.: PCT/US2021/050936.; International PCT Application No. PCT/US20/13618 Title: BISPHOSPHONATE CONJUGATES AND USES THEREOF; Methods and Compounds for Neoantigen Vaccines Provisional Application Serial No.: 63/166,697.; Neoantigen-Informed Tumor-Infiltrating Lymphocyte Cancer Immunotherapy. WO 2021/222855. PCT/US2021/030331; Peptide Inhibitors Targeting the TBL1-Beta-Catenin Complex. Provisional Application Serial No.: 63/159,882; Provisional Application No. 62/961,930. Title: PepSeq as a platform to identify synthetic molecular binding agents; Provisional application number: 62/818,037 Title: Trisubstituted Pyrazolo [1, 5-a] Pyrimidine Compounds and Methods of Use Thereof
 
Ronan Joseph Kelly
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sanyo; Eisai; EMD Serono; Ipsen; Lilly; McKesson; Medscape; Merck; Novartis; Onc Live; Peerview; Philips Healthcare; Pieris Pharmaceuticals; Takeda
Speakers' Bureau - AstraZeneca/Daiichi Sankyo; Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst)
Expert Testimony - Merck
 
Fumiyoshi Okano
Employment - Toray Industries
Leadership - Toray Industries
 
Daniel D. Von Hoff
Employment - McKesson
Stock and Other Ownership Interests - AADi; Anthem Inc; CerRx; FORMA Therapeutics; Medtronic; Origin Commercial Advisors; Orpheus Bioscience; Stingray Therapeutics; Stromatis Pharma; SynDevRx; Systems Oncology; UnitedHealthcare
Consulting or Advisory Role - Agastiya Biotech; Agenus; AiMed; AlaMab Therapeutics; Alpha Cancer Technologies; Amunix; Aptose Biosciences; Atalion Therapeutics; Athenex; Avesta76 Therapeutics; Axis Therapeutics; BioXCel therapeutics; Bryologyx; CanBas; Caribou Biosciences; Catamaran Bio; Codiak Biosciences; Compass Therapeutics; Coordination Pharmaceuticals; Corcept Therapeutics; CV6 Therapeutics; Cytocom; Decoy Biosystems; DNAtrix; EMD Serono; Erimos Pharmaceuticals; EXACT Therapeutics; Fujifilm; Geistlich Pharma; Genzada Pharmaceuticals; Gimbal; GiraFpharma; GlaxoSmithKline; HUYA Bioscience International; ImaginAb; Imaging Endpoints; Immodulon Therapeutics; ImmuneOncia; Immunophotonics; L.E.A.F. Pharmaceuticals; Lixte Biotechnology; Lycia Therapeutics; NeoTx; NGM Biopharmaceuticals; Nirogy Therapeutics; Novita Pharmaceuticals; Noxxon Pharma; Oncology Venture; Oncolyze; OnQuality Pharmaceuticals; Orphagen Pharmaceuticals; Pfizer; Phosplatin Therapeutics; RadImmune; Reflexion Medical; Reglagene; RenovoRx; Samumed; Seagen; Sellas Life Sciences; Senhwa Biosciences; SignaBlok; Sirnaomics; SonaCare Medical; SOTIO; Sumitomo Dainippon Pharma Oncology; Synergene; TD2; Thirona Biosciences; Tolero Pharmaceuticals; Verily; Vicus Therapeutics; Viracta Therapeutics; Vivacitas Oncology; Xenter; Xerient
Research Funding - Abbvie (Inst); Aduro Biotech (Inst); Celgene (Inst); Cleave Biosciences (Inst); CytRx Corporation (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Endocyte (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Merrimack (Inst); Minneamrita Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Phoenix Biotech (Inst); Plexxikon (Inst); Samumed (Inst); Strategia (Inst)
Patents, Royalties, Other Intellectual Property - 2-aryl-pyridylazoles for the Treatment of Solid Tumors such as Pancreatic Cancer (pending); Intramedullary Catheter; Methods and Kits to Predict Therapeutic Outcome of BTK Inhibitors (pending); Methods of Human Prostate Cancer; Methods, Compounds and Compositions with Genotype Selective Anticancer Activity (pending); Muscle Fatigue Substance Cytokines and Methods of Inhibiting Tumor Growth Therewith (pending); Protein Kinase Inhibitors (pending); Targeting a Protein PRC1 for the Treatment of Pancreatic Cancer (pending); Targeting a Protein Tyrosine Phosphotase-PRL-1 for the Treatment of Pancreatic Cancer (pending); Targeting Ecto-5-Nucleotidase (Cd73) for the Treatment of Pancreatic Cancer; Targeting Ecto-5-Nucleotidase (CD73) for the Treatment of Pancreatic Cancer (pending); Targeting Site-2 Protease (S2P) for the Treatment of Pancreatic Cancer (pending); Use of 5,6-Dihydro-5-Azacytidine in the Treatment of Prostate Cancer
 
Jean-Yves Blay
Leadership - Innate Pharma
Honoraria - AstraZeneca; Bayer; BMS; Deciphera; Ignyta; MSD; PharmaMar; Roche
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Deciphera; Deciphera; Deciphera; Karyopharm Therapeutics; Pharmamar; Roche
Research Funding - AstraZeneca (Inst); Bayer (Inst); BMS (Inst); DEciphera (Inst); GlaxoSmithKline (Inst); MSD (Inst); Novartis (Inst); OSE Pharma (Inst); Pharmamar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Roche